Literature DB >> 22579686

Apoptosis inhibitor of macrophage (AIM) diminishes lipid droplet-coating proteins leading to lipolysis in adipocytes.

Yoshihiro Iwamura1, Mayumi Mori, Katsuhiko Nakashima, Toshiyuki Mikami, Katsuhisa Murayama, Satoko Arai, Toru Miyazaki.   

Abstract

Under fasting conditions, triacylglycerol in adipose tissue undergoes lipolysis to supply fatty acids as energy substrates. Such lipolysis is regulated by hormones, which activate lipases via stimulation of specific signalling cascades. We previously showed that macrophage-derived soluble protein, AIM induces obesity-associated lipolysis, triggering chronic inflammation in fat tissue which causes insulin resistance. However, the mechanism of how AIM mediates lipolysis remains unknown. Here we show that AIM induces lipolysis in a manner distinct from that of hormone-dependent lipolysis, without activation or augmentation of lipases. In vivo and in vitro, AIM did not enhance phosphorylation of hormone-sensitive lipase (HSL) in adipocytes, a hallmark of hormone-dependent lipolysis activation. Similarly, adipose tissue from obese AIM-deficient and wild-type mice showed comparable HSL phosphorylation. Consistent with the suppressive effect of AIM on fatty acid synthase activity, the amount of saturated and unsaturated fatty acids was reduced in adipocytes treated with AIM. This response ablated transcriptional activity of peroxisome proliferator-activated receptor (PPARγ), leading to diminished gene expression of lipid-droplet coating proteins including fat-specific protein 27 (FSP27) and Perilipin, which are indispensable for triacylglycerol storage in adipocytes. Accordingly, the lipolytic effect of AIM was overcome by a PPARγ-agonist or forced expression of FSP27, while it was synergized by a PPARγ-antagonist. Overall, distinct modes of lipolysis appear to take place in different physiological situations; one is a supportive response against nutritional deprivation achieved by enhancing lipase activity, and the other is a pathological consequence of obesity, causing subclinical inflammation and metabolic disorders, mediated by abolishing droplet-coating proteins.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22579686     DOI: 10.1016/j.bbrc.2012.05.018

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice.

Authors:  Satoko Arai; Kento Kitada; Tomoko Yamazaki; Ryosuke Takai; Xizhong Zhang; Yoji Tsugawa; Ryoichi Sugisawa; Ayaka Matsumoto; Mayumi Mori; Yasunori Yoshihara; Kent Doi; Natsumi Maehara; Shunsuke Kusunoki; Akiko Takahata; Eisei Noiri; Yusuke Suzuki; Naoki Yahagi; Akira Nishiyama; Lakshman Gunaratnam; Tomoko Takano; Toru Miyazaki
Journal:  Nat Med       Date:  2016-01-04       Impact factor: 53.440

Review 2.  AIM associated with the IgM pentamer: attackers on stand-by at aircraft carrier.

Authors:  Toru Miyazaki; Tomoko Yamazaki; Ryoichi Sugisawa; M Eric Gershwin; Satoko Arai
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

3.  MafB deficiency accelerates the development of obesity in mice.

Authors:  Mai Thi Nhu Tran; Michito Hamada; Megumi Nakamura; Hyojung Jeon; Risa Kamei; Yuki Tsunakawa; Kaushalya Kulathunga; Yuan-Yu Lin; Kumiko Fujisawa; Takashi Kudo; Satoru Takahashi
Journal:  FEBS Open Bio       Date:  2016-04-21       Impact factor: 2.693

4.  Tricking an ancient immune function to eradicate hepatocellular carcinoma.

Authors:  Toru Miyazaki; Satoko Arai
Journal:  Mol Cell Oncol       Date:  2015-01-23

5.  Impact of feline AIM on the susceptibility of cats to renal disease.

Authors:  Ryoichi Sugisawa; Emiri Hiramoto; Shigeru Matsuoka; Satomi Iwai; Ryosuke Takai; Tomoko Yamazaki; Nobuko Mori; Yuki Okada; Naoki Takeda; Ken-Ichi Yamamura; Toshiro Arai; Satoko Arai; Toru Miyazaki
Journal:  Sci Rep       Date:  2016-10-12       Impact factor: 4.379

Review 6.  Impacts of the apoptosis inhibitor of macrophage (AIM) on obesity-associated inflammatory diseases.

Authors:  Satoko Arai; Toru Miyazaki
Journal:  Semin Immunopathol       Date:  2013-11-27       Impact factor: 9.623

7.  Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C.

Authors:  Kumiko Mera; Hirofumi Uto; Seiichi Mawatari; Akio Ido; Yozo Yoshimine; Tsuyoshi Nosaki; Kohei Oda; Kazuaki Tabu; Kotaro Kumagai; Tsutomu Tamai; Akihiro Moriuchi; Makoto Oketani; Yuko Shimada; Masaaki Hidaka; Susumu Eguchi; Hirohito Tsubouchi
Journal:  BMC Gastroenterol       Date:  2014-02-13       Impact factor: 3.067

8.  The scavenger protein apoptosis inhibitor of macrophages (AIM) potentiates the antimicrobial response against Mycobacterium tuberculosis by enhancing autophagy.

Authors:  Lucía Sanjurjo; Núria Amézaga; Cristina Vilaplana; Neus Cáceres; Elena Marzo; Marta Valeri; Pere-Joan Cardona; Maria-Rosa Sarrias
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

9.  Stabilization and augmentation of circulating AIM in mice by synthesized IgM-Fc.

Authors:  Toshihiro Kai; Tomoko Yamazaki; Satoko Arai; Toru Miyazaki
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

10.  Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

Authors:  Tomoko Yamazaki; Mayumi Mori; Satoko Arai; Ryosuke Tateishi; Masanori Abe; Mihoko Ban; Akemi Nishijima; Maki Maeda; Takeharu Asano; Toshihiro Kai; Kiyohiro Izumino; Jun Takahashi; Kayo Aoyama; Sei Harada; Toru Takebayashi; Toshiaki Gunji; Shin Ohnishi; Shinji Seto; Yukio Yoshida; Yoichi Hiasa; Kazuhiko Koike; Ken-ichi Yamamura; Ken-ichiro Inoue; Toru Miyazaki
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.